Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T22583
|
||||
| Former ID |
TTDC00158
|
||||
| Target Name |
Sodium/glucose cotransporter 2
|
||||
| Gene Name |
SLC5A4
|
||||
| Synonyms |
Low affinity sodium-glucose cotransporter; Na(+)/glucose cotransporter 2; SGLT2; Sodium dependent glucose transporter2; SLC5A4
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Diabetes [ICD9: 253.5, 588.1; ICD10: E23.2, N25.1] | ||||
| Type 1/2 diabetes [ICD9: 250, 278; ICD10: E08-E13] | |||||
| Type 2 diabetes [ICD9: 250; ICD10: E11] | |||||
| Function |
Sodium-dependent glucose transporter.
|
||||
| BioChemical Class |
Solute:sodium symporter
|
||||
| Target Validation |
T22583
|
||||
| UniProt ID | |||||
| Sequence |
MASTVSPSTIAETPEPPPLSDHIRNAADISVIVIYFLVVMAVGLWAMLKTNRGTIGGFFL
AGRDMAWWPMGASLFASNIGSNHYVGLAGTGAASGVATVTFEWTSSVMLLILGWIFVPIY IKSGVMTMPEYLKKRFGGERLQVYLSILSLFICVVLLISADIFAGAIFIKLALGLDLYLA IFILLAMTAVYTTTGGLASVIYTDTLQTIIMLIGSFILMGFAFNEVGGYESFTEKYVNAT PSVVEGDNLTISASCYTPRADSFHIFRDAVTGDIPWPGIIFGMPITALWYWCTNQVIVQR CLCGKDMSHVKAACIMCAYLKLLPMFLMVMPGMISRILYTDMVACVVPSECVKHCGVDVG CTNYAYPTMVLELMPQGLRGLMLSVMLASLMSSLTSIFNSASTLFTIDLYTKMRKQASEK ELLIAGRIFVLLLTVVSIVWVPLVQVSQNGQLIHYTESISSYLGPPIAAVFVLAIFCKRV NEQGAFWGLMVGLAMGLIRMITEFAYGTGSCLAPSNCPKIICGVHYLYFSIVLFFGSMLV TLGISLLTKPIPDVHLYRLCWVLRNSTEERIDIDAEEKSQEETDDGVEEDYPEKSRGCLK KAYDLFCGLQKGPKLTKEEEEALSKKLTDTSERPSWRTIVNINAILLLAVVVFIHGYYA |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | RG7201 | Drug Info | Phase 3 | Type 2 diabetes | [1] |
| SaxaDapa FDC | Drug Info | Phase 3 | Diabetes | [2], [3] | |
| Remogli ozin-etabonate | Drug Info | Phase 2 | Type 2 diabetes | [4] | |
| Remogliflozin etabonate | Drug Info | Phase 2 | Type 1/2 diabetes | [5] | |
| Blocker | ISIS-5GLT2rx | Drug Info | [6] | ||
| Remogliflozin etabonate | Drug Info | [7] | |||
| Modulator | Remogli ozin-etabonate | Drug Info | [8] | ||
| RG7201 | Drug Info | [1] | |||
| SaxaDapa FDC | Drug Info | [2], [3] | |||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| Reactome | Hexose transport | ||||
| Na+-dependent glucose transporters | |||||
| Inositol transporters | |||||
| WikiPathways | NRF2 pathway | ||||
| References | |||||
| REF 1 | Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65. | ||||
| REF 2 | Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7. | ||||
| REF 3 | The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010 Nov;12(11):1004-12. | ||||
| REF 4 | Clinical pipeline report, company report or official report of Bhv pharma. | ||||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021813) | ||||
| REF 6 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). | ||||
| REF 7 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | ||||
| REF 8 | Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.